Insmed (INSM) PT Lowered to $203 at BofA Securities
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/12/2026
- S&P 500 ends higher as CoreWeave results fuel AI optimism
- Oil prices edge up as investors weigh US-Iran talks deadlock against lower demand
- CoreWeave soars after fifth straight quarter of record revenue, raised guide
- Four key things investors will watch in Nvidia's earnings next week
- Silver could surge to $90 as investment demand takes over, Citi says
- Lumentum Holdings (LITE) Tops Q4 EPS by 28c, Beats on Revenue; Offers Q1 Guidance
- Crude Inventory Rose 17.2 Million Barrels Last Week - EIA
- Aurora Cannabis rejects Curaleaf's unsolicited $4-per-share takeover bid
- AbCellera Biologics (ABCL) PT Raised to $30 at Truist on 'best-in-class potential'
- Comscore plans restructuring with $20M-$25M in cost cuts
- After-Hours Movers: CSCO, COHR, HLIT, CBRS, STUB, ENS
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
Insmed (INSM) PT Lowered to $195 at RBC Capital
December 18, 2025 4:19 AM ESTRBC Capital analyst Leonid Timashev lowered the price target on Insmed (NASDAQ: INSM) to $195.00 (from $215.00) while maintaining a Outperform rating.
The analyst comments "This afternoon, INSM reported that their ph.II BiRCH study of brensocatib in CRSsNP failed, and the program... More
Insmed (INSM) PT Lowered to $195 at Leerink Partners
December 18, 2025 4:11 AM ESTLeerink Partners analyst Joseph P. Schwartz lowered the price target on Insmed (NASDAQ: INSM) to $195.00 (from $227.00) while maintaining a Outperform rating.
The analyst comments "After the market close, INSM reported that the Phase 2 BiRCh trial for brensocatib in chronic rhinosinusitis without nasal polyps (CRSsNP) missed on the primary and all secondary endpoints. While we had hoped that the... More
Insmed (INSM) PT Lowered to $167 at Wolfe Research
December 18, 2025 3:53 AM ESTWolfe Research analyst Andy Chen lowered the price target on Insmed (NASDAQ: INSM) to $167.00 (from $229.00) while maintaining a Outperform rating.
The analyst comments "Postmarket, stock is down 19% (consistent with a priori buyside expectation of -20 to -25%). We continue to believe that buyside is assigning slightly less than $6B peak sales to Brinsupri in bronchiectasis, suggesting that the current stock level... More
Insmed discontinues nasal polyps drug program after trial fails
December 17, 2025 4:01 PM ESTInsmed Incorporated (NASDAQ: INSM) announced that its Phase 2b BiRCh study of brensocatib for chronic rhinosinusitis without nasal polyps failed to meet primary or secondary efficacy endpoints, leading the company to discontinue the program.
The study tested two doses of brensocatib against placebo in 288 patients over 24 weeks. Results showed placebo patients had a least squares mean... More
Insmed (INSM) halted, news pending
December 17, 2025 4:01 PM ESTInsmed (NASDAQ: INSM) halted, news pending
... MoreInsmed (INSM) PT Raised to $230 at Cantor Fitzgerald Brenso Potential
December 16, 2025 6:48 AM ESTCantor Fitzgerald analyst Olivia Brayer raised the price target on Insmed (NASDAQ: INSM) to $230.00 (from $216.00) while maintaining a Overweight rating.
The analyst commented, "We think brenso has a good chance to show a benefit in CRSsNP (on top of a steroid... More
Insmed (INSM) PT Raised to $234 at Wells Fargo
December 16, 2025 6:20 AM ESTWells Fargo analyst Ben Burnett raised the price target on Insmed (NASDAQ: INSM) to $234.00 (from $217.00) while maintaining a Overweight rating.... More
